Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $208.8 million.

  • Gossamer Bio's Liabilities and Shareholders Equity fell 4048.66% to $208.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 1929.43%. This contributed to the annual value of $315.3 million for FY2024, which is 108.23% up from last year.
  • As of Q3 2025, Gossamer Bio's Liabilities and Shareholders Equity stood at $208.8 million, which was down 4048.66% from $240.9 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Liabilities and Shareholders Equity ranged from a high of $373.4 million in Q2 2024 and a low of $181.7 million during Q2 2023
  • Its 4-year average for Liabilities and Shareholders Equity is $281.8 million, with a median of $280.6 million in 2025.
  • As far as peak fluctuations go, Gossamer Bio's Liabilities and Shareholders Equity surged by 10547.8% in 2024, and later crashed by 4048.66% in 2025.
  • Over the past 4 years, Gossamer Bio's Liabilities and Shareholders Equity (Quarter) stood at $272.4 million in 2022, then grew by 14.49% to $311.9 million in 2023, then increased by 1.08% to $315.3 million in 2024, then plummeted by 33.77% to $208.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $208.8 million for Q3 2025, versus $240.9 million for Q2 2025 and $280.6 million for Q1 2025.